Novartis ASPIRES To Drive Use of Investigational Anti-Hypertensive Rasilez
Two outcomes intervention studies of aliskiren, which is currently pending at FDA, will begin in the first half of 2007.
Two outcomes intervention studies of aliskiren, which is currently pending at FDA, will begin in the first half of 2007.